Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Teva and Prestige Biopharma enter license agreement for Tuznue (trastuzumab biosimilar) commercialization in Europe

Written by | 4 Nov 2025

Teva Pharmaceutical Industries Ltd. entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin, across a majority of European markets…. read more.

Teva and Samsung Bioepis announce biosimilar Epysqli (eculizumab-aagh) injection now available in the United States

Written by | 7 May 2025

Teva Pharmaceutical Industries Ltd. , and Samsung Bioepis Co., Ltd. announced the availability of Epysqli (eculizumab-aagh) in the U.S. Epysqli is a biosimilar to Soliris (eculizumab) for the… read more.

Teva announces FDA filling acceptance for Ajovy (fremanezumab) in pediatric episodic migraine prevention

Written by | 19 Apr 2025

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA  has accepted its supplemental Biologics License Application (sBLA) for  Ajovy (fremanezumab-vfrm) to expand the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.